Lexaria Bioscience Corp Ordinary Shares LEXX 深 滬
已收盤 09-19 16:00:00 美东时间
1.24
+0.020
+1.64%
華盛通- 最 高1.40
- 今 開1.20
- 成交量 47.36万股
- 最 低 1.16
- 昨 收 1.22
- 總市值 2425.34万
- 52周最高 3.3915
- 市盈率 靜 --
- 換手率 2.42%
- 52周最低 0.7749
- 委 比 -99.81%
- 總股本 1955.92万
- 歷史最高 12.50
- 量 比 1.65
- 振 幅 19.67%
- 歷史最低 0.6488
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lexaria Bioscience Announces Results From Fluorescently Tagged Semaglutide Rodent Biodistribution Study
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyLexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery
09-19 23:22
Lexaria Bioscience’s DehydraTECH Boosts Semaglutide Brain Delivery
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience has ann...
09-19 23:07
Lexaria Bioscience's Contract Research Organization Completes Last Patent Last Visit Study Milestone In Lexaria's Phase 1b Glucagon-Like Peptide-1 Study In Australia, GLP-1-H24-4
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the
08-14 21:23
Lexaria Bioscience Targets GLP-1 Market with DehydraTECH Innovation
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience is posi...
08-06 22:42
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf
07-31 22:58
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lexicon Pharmaceuticals announced that its common stock has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid price met the $1.00 per share requirement for ten consecutive business days. This update was previously disclosed in the Company’s Form 8-K filed on July 28, 2025. Lexicon, a biopharmaceutical company, focuses on pioneering innovative medicines through its Genome5000™ program, targeting diseases like heart fail...
07-31 12:00
Lexaria’s DehydraTECH Technology Poised to Transform GLP-1 Industry
Lexaria Bioscience ( ($LEXX) ) just unveiled an announcement. Lexaria Bioscienc...
07-23 23:09
Lexaria's DehydraTECH Targets Side Effects In GLP-1 Market, Offers Relief For Semaglutide, Tirzepatide, And Liraglutide Users
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:29
Lexaria Bioscience Prpvides Strategic Update Of Glucagon-Like Peptide-1
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:28
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DIH Holding US (NASDAQ:DHAI) shares rose 35.1% to $0.34 during Friday'...
07-19 05:06
